1.0hollandbiohttps://www.hollandbio.nl/en/rich600338<blockquote class="wp-embedded-content" data-secret="MF6J0rNE2b"><a href="https://www.hollandbio.nl/en/nieuws/e17-million-for-kiadis-pharma/">€17 million for Kiadis Pharma</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.hollandbio.nl/en/nieuws/e17-million-for-kiadis-pharma/embed/#?secret=MF6J0rNE2b" width="600" height="338" title="“€17 million for Kiadis Pharma” — hollandbio" data-secret="MF6J0rNE2b" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.hollandbio.nl/wp-includes/js/wp-embed.min.js </script> Kiadis Pharma, a clinical-stage biopharmaceutical company, today announces that it has closed private placements totalling EUR 17 million with two healthcare focused investors. Kiadis plans to use the proceeds from these transactions to continue to fund the development of the its K-NK-cell therapy programs. Arthur Lahr, CEO of Kiadis commented, “We are very pleased to […]https://www.hollandbio.nl/wp-content/uploads/2025/01/hb-opengraph_illu.png1200675